identifying novel digital measures for fatigue and sleep disturbances that will provide more objective, sensitive and reliable measures of the severity and impact of these symptoms in the person’s normal surrounding.
one year longitudinal study with approximately 2000 subjects will be conducted
Participants with neurological or immunological disorders from various countries will be screened and recruited
Participants with neurological or immunological disorders from various countries will be screened and recruited
All participants will be given a combination of 2-4 digital devices for use in their own environment for several periods
Data on fatigue, sleep, selected activities of daily living and other relevant contextual information will be collected by smartphone several times a day while using the devices
In order to establish which devices are suitable for use, complex data analysis will be performed
The devices that met the criteria will be considered for future use in clinical trials
The novel clinically validated digital endpoint will be able to:
Dear readers, The Clinical Observational Study (COS) is on a roll, and we are proud to present the first Newsletter of the IDEA-FAST COS, with the latest recruitment status. The COS is an ambitious study
We are delighted to announce that University of Glasgow has recruited their first participant in the IDEA-FAST Clinical Observational Study. So far 13 sites opened for recruitment and 7 more are expected to soon join!
We have great news! Devon and Exter NHS started the recruitment of participants in the clinical observational study of the IDEA-FAST project, joining the other clinical sites that are now on a roll. We congratulate
The IDEA-FAST Clinical Observational Study is on a roll! We are proud to announce that Stavanger University recruited last week their first patient and they are ready to start. We are looking forward to one
We are delighted to announce that Newcastle University has recruited two patients for the start of the IDEA-FAST Clinical Observation Study. The goal of the study and indeed the IDEA-FAST project is to identify, profile
On May 30 and 31, members of IDEA-FAST met in Kiel, Germany, to prepare for the start of the Clinical Observational Study (COS). The University Medical Centre Schleswig-Holstein as sponsor of the COS with their
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853981. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and PARKINSON’S DISEASE SOCIETY OF THE UNITED KINGDOM LBG.
